DOP2012000277A - Comprimido de desintegracion por via oral que contiene acarbosa - Google Patents

Comprimido de desintegracion por via oral que contiene acarbosa

Info

Publication number
DOP2012000277A
DOP2012000277A DO2012000277A DO2012000277A DOP2012000277A DO P2012000277 A DOP2012000277 A DO P2012000277A DO 2012000277 A DO2012000277 A DO 2012000277A DO 2012000277 A DO2012000277 A DO 2012000277A DO P2012000277 A DOP2012000277 A DO P2012000277A
Authority
DO
Dominican Republic
Prior art keywords
deintegration
compressed
acarbose
via containing
containing acarbose
Prior art date
Application number
DO2012000277A
Other languages
English (en)
Inventor
Axel Schneeweis
Tobias Laich
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of DOP2012000277A publication Critical patent/DOP2012000277A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Era un objeto de la presente invención proporcionar un comprimido de desintegración por vía oral (ODT) para el inhibidor de la glucosidasa acarbosa. El objetivo se consigue con un comprimido de desintegración por vía oral que contiene un 1-30 % de acarbosa y un 40-90 % de vehículo soluble en agua. Con el fin de obtener las propiedades deseadas, se tienen que compactar previamente los ingredientes y mezclar previamente con un vehículo insoiuble.
DO2012000277A 2010-04-27 2012-10-26 Comprimido de desintegracion por via oral que contiene acarbosa DOP2012000277A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10161114 2010-04-27

Publications (1)

Publication Number Publication Date
DOP2012000277A true DOP2012000277A (es) 2012-12-15

Family

ID=44344015

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000277A DOP2012000277A (es) 2010-04-27 2012-10-26 Comprimido de desintegracion por via oral que contiene acarbosa

Country Status (27)

Country Link
US (1) US20130131003A1 (es)
EP (1) EP2563329B1 (es)
JP (1) JP5944378B2 (es)
KR (1) KR101788350B1 (es)
CN (2) CN102905687A (es)
AU (1) AU2011247642C1 (es)
BR (1) BR112012027303A2 (es)
CA (1) CA2797365A1 (es)
CL (1) CL2012003011A1 (es)
CO (1) CO6640213A2 (es)
CR (1) CR20120548A (es)
CU (1) CU20120152A7 (es)
DO (1) DOP2012000277A (es)
EC (1) ECSP12012279A (es)
ES (1) ES2623025T3 (es)
GT (1) GT201200290A (es)
IL (1) IL222368B (es)
MX (1) MX348865B (es)
MY (1) MY179724A (es)
NZ (1) NZ603199A (es)
PE (1) PE20130403A1 (es)
PH (1) PH12012502139A1 (es)
SG (2) SG184851A1 (es)
SI (1) SI2563329T1 (es)
TW (1) TWI556823B (es)
UA (1) UA111155C2 (es)
WO (1) WO2011134962A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201100150A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Suda çözünür dozaj formları
WO2013115738A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Micronized acarbose
WO2013115741A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical compositions comprising alpha-glucosidase inhibitor
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
CN104013590A (zh) * 2014-05-09 2014-09-03 万特制药(海南)有限公司 一种含阿卡波糖的药物组合物及其制备方法
UA122403C2 (uk) * 2014-12-17 2020-11-10 Емпрос Фарма Аб Композиція орлістату та акарбози з модифікованим вивільненням для лікування ожиріння і пов'язаних метаболічних порушень
CN105213341A (zh) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 一种阿卡波糖片及其制备方法
CN113081984B (zh) * 2021-04-19 2023-06-02 北京阳光诺和药物研究股份有限公司 一种阿卡波糖口崩片及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134591A1 (de) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
JPH10182687A (ja) * 1996-10-21 1998-07-07 Bayer Yakuhin Kk アカルボースの貯蔵安定化法
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
KR100682836B1 (ko) * 2004-12-06 2007-02-15 엘지전자 주식회사 유기 전계 발광 소자
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
JP4931907B2 (ja) * 2006-02-27 2012-05-16 パナソニック株式会社 ウェアラブル端末、および、携帯撮像収音装置、およびそれらを実現する装置、方法、プログラム
FI20070521A7 (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CN101411715B (zh) * 2007-10-19 2012-03-28 杭州华东医药集团生物工程研究所有限公司 含有阿卡波糖的药物组合物
JP5291324B2 (ja) * 2007-11-01 2013-09-18 沢井製薬株式会社 口腔内崩壊錠
JP2009114113A (ja) * 2007-11-06 2009-05-28 Nipro Corp 口腔内崩壊錠及びその製造方法
JP2011506279A (ja) * 2007-12-08 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 経口で分散可能な錠剤
CN105496978A (zh) * 2007-12-21 2016-04-20 阿代尔制药股份有限公司 替马西泮的口腔崩解片组合物
BRPI0914164B1 (pt) * 2008-06-20 2019-04-30 Merck Patent Gmbh Comistura para produção de comprimidos de desintegração rápida em um processo de formação de comprimido direto, seus usos, e formulações de comprimido

Also Published As

Publication number Publication date
GT201200290A (es) 2014-09-24
ES2623025T3 (es) 2017-07-10
MY179724A (en) 2020-11-11
WO2011134962A2 (en) 2011-11-03
IL222368A0 (en) 2012-12-31
BR112012027303A2 (pt) 2017-10-24
MX348865B (es) 2017-07-03
CN102905687A (zh) 2013-01-30
PE20130403A1 (es) 2013-04-13
CA2797365A1 (en) 2011-11-03
PH12012502139A1 (en) 2022-03-21
SI2563329T1 (sl) 2017-05-31
AU2011247642C1 (en) 2015-11-12
MX2012012459A (es) 2012-11-21
UA111155C2 (uk) 2016-04-11
EP2563329A2 (en) 2013-03-06
JP5944378B2 (ja) 2016-07-05
AU2011247642A1 (en) 2012-11-08
CL2012003011A1 (es) 2013-04-19
NZ603199A (en) 2014-05-30
EP2563329B1 (en) 2017-04-12
SG184851A1 (en) 2012-11-29
CR20120548A (es) 2013-03-11
CO6640213A2 (es) 2013-03-22
KR101788350B1 (ko) 2017-10-19
IL222368B (en) 2018-11-29
KR20130062926A (ko) 2013-06-13
CU20120152A7 (es) 2014-02-28
TW201141490A (en) 2011-12-01
WO2011134962A3 (en) 2012-05-03
CN106924199A (zh) 2017-07-07
AU2011247642B2 (en) 2015-05-14
TWI556823B (zh) 2016-11-11
US20130131003A1 (en) 2013-05-23
JP2013525404A (ja) 2013-06-20
ECSP12012279A (es) 2012-11-30
SG10201505844WA (en) 2015-09-29

Similar Documents

Publication Publication Date Title
CR20120548A (es) Comprimido de desintegración por vía oral que contiene acarbosa
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
CO6771428A2 (es) Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales
CL2016001547A1 (es) Composiciones para el cuidado oral
ECSP13012715A (es) Método para producir preparados farmacéuticos con contenido de ibp
GT201400196A (es) Compuestos de heterociclilo
GT201300266A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
GT201200165A (es) Triazolopiridinas
MX338712B (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
BR112012032172A2 (pt) método para produzir um álcool e composição
MX2012002089A (es) Composiciones alcoholicas que tienen un riesgo reducido de acetaldehidemia.
MX2012008717A (es) Composiciones para el cuidado oral.
PE20151979A1 (es) Compuestos quimicos
BR112015008912A2 (pt) composições solidificáveis compreendendo volastonita e pedra-pomes e métodos de uso
AR081670A1 (es) Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
MX2013001234A (es) Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a.
CL2013003093A1 (es) Composiciones que comprende cation de polihidroxioxoaluminio detectable por rmn; metodo de fabricacion de los mismos; y su uso.
CR20120461A (es) Hidrato del hidrobromuro de agomelatina y preparación de éste
HN2009001330A (es) Compuestos novedosos activos como antagonistas de receptore muscarinico
AR089114A1 (es) PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
BR112013010491A2 (pt) pó de poliol e polissacarídeo comprimível e altamente viscoso
CL2013000335A1 (es) Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension.
EP2538960A4 (en) surfactant
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.